摘要
心血管疾病的发病率呈现逐年上升的趋势,对人们的健康构成严重的威胁。目前质子泵抑制剂联合氯吡格雷预防与治疗心血管疾病是临床上常用的方案。质子泵抑制剂与氯吡格雷均经肝脏酶代谢,联合应用时,质子泵抑制剂可能会与氯吡格雷发生相互作用,影响氯吡格雷的药物代谢与药效特征,甚至可能会增加心血管事件的发生率。该文从氯吡格雷的药物代谢、临床疗效、临床评价等方面,依据现有研究文献,对质子泵抑制剂联合氯吡格雷治疗心血管疾病的安全性进行评价。
The incidence of cardiovascular diseases sees a yearly increasing trend , which is a serious threat to the health of people.Currently proton pump inhibitor combined with clopidogrel is a common clinical scheme,both of which are metabolized by liver enzymes,and the proton pump inhibitor might interact with clopidogrel and affect the drug metabolism and pharmacodynamic characteristics of clopidogrel , or even increase the incidence of cardiovascular events.Here is to evaluate the safety of the combined application of proton pump inhibitor and clopidogrel from the aspects of drug metabolism ,clinical effect and clinical evalua-tion of clopidogrel.
出处
《医学综述》
2015年第14期2606-2608,共3页
Medical Recapitulate
基金
上海市嘉定区卫生局重点学科建设计划项目(ZD001)
关键词
心血管疾病
质子泵抑制剂
氯吡格雷
安全性
Caridovascular diseases
Proton pump inhibitor
Clopidogrel
Safety
